The study is a dose-escalation and dose-expansion study to evaluate the safety,
tolerability, and pharmacokinetics of ASKG915 as a single agent or in combination with
standard of care (SOC) in patients with selected types of advanced solid tumors.
Study sponsor and potential other locations can be found on ClinicalTrials.gov for NCT05867420.
Locations matching your search criteria
United States
Pennsylvania
Pittsburgh
University of Pittsburgh Cancer Institute (UPCI)Status: Active
Name Not Available
Monotherapy:
A dose-escalation (Part A) and expansion (Part B) study of ASKG915 monotherapy was
initiated to evaluate the safety, tolerability, pharmacokinetics (PK), and
pharmacodynamics (PD) in patients with advanced solid tumors.
Combination therapy:
A dose-optimization (Part C) srudy of ASKG915 in combination with standard of care (SOC)
in patients was conducted to evaluate the safety, tolerability, pharmacokinetics (PK),
and pharmacodynamics (PD) in patients with selected types of advanced solid tumors.
Lead OrganizationAskGene Pharma, Inc.
Principal InvestigatorBarbara Hickingbottom
